Investment Analysts’ updated eps estimates for Monday, March 16th:
Canaan (NASDAQ:CAN) had its buy rating reaffirmed by analysts at Rosenblatt Securities. Rosenblatt Securities currently has a $2.25 price target on the stock.
Coya Therapeutics (NASDAQ:COYA) had its buy rating reiterated by analysts at Chardan Capital. The firm currently has a $14.00 target price on the stock.
CervoMed (NASDAQ:CRVO) had its buy rating reiterated by analysts at D. Boral Capital. They currently have a $31.00 price target on the stock.
Torrid (NYSE:CURV) had its market perform rating reiterated by analysts at Telsey Advisory Group. The firm currently has a $2.00 price target on the stock.
Distribution Solutions Group (NASDAQ:DSGR) had its outperform rating reaffirmed by analysts at Barrington Research. They currently have a $35.00 price target on the stock.
Enterprise Group (TSE:E) was downgraded by analysts at Raymond James Financial, Inc. from an outperform rating to a market perform rating. Raymond James Financial, Inc. currently has C$1.50 price target on the stock, down from their previous price target of C$2.00.
Emerald (NYSE:EEX) had its buy rating reissued by analysts at Rosenblatt Securities. They currently have a $7.70 target price on the stock.
Micron Technology (NASDAQ:MU) had its buy rating reiterated by analysts at Rosenblatt Securities. The firm currently has a $500.00 target price on the stock.
NRx Pharmaceuticals (NASDAQ:NRXP) had its buy rating reaffirmed by analysts at D. Boral Capital. D. Boral Capital currently has a $34.00 price target on the stock.
Palvella Therapeutics (NASDAQ:PVLA) had its buy rating reiterated by analysts at Chardan Capital. Chardan Capital currently has a $210.00 price target on the stock.
Stoneridge (NYSE:SRI) was downgraded by analysts at Barrington Research from an outperform rating to a market perform rating.
Receive News & Ratings for Canaan Inc Sponsored ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Canaan Inc Sponsored ADR and related companies with MarketBeat.com's FREE daily email newsletter.
